Koers Biofrontera AG OTC Markets
Aandelen
BFRA
US09075G1058
Farmaceutische producten
Omzet 2021 | 28,79 mln. 30,78 mln. | Omzet 2022 | 25,74 mln. 27,52 mln. | Marktkapitalisatie | 97,31 mln. 104 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | 38 mln. 40,63 mln. | Nettowinst (verlies) 2022 | -44 mln. -47,05 mln. | EV/omzet 2021 | 2,79 x |
Nettoliquiditeiten 2021 | 3,61 mln. 3,86 mln. | Nettoliquiditeiten 2022 | 4,88 mln. 5,21 mln. | EV/omzet 2022 | 3,59 x |
K/w-verhouding 2021 |
2,18
x | K/w-verhouding 2022 |
-1,98
x | Werknemers | 92 |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 32,4% |
Recentste transcriptie over Biofrontera AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Director of Finance/CFO | 55 | 12-09-22 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 63 | 14-12-21 | |
Director/Board Member | - | 14-12-21 | |
Heikki Lanckriet
BRD | Director/Board Member | 47 | 14-12-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |